Metformin is the first-line drug treatment for type 2 diabetes. Globally, over 100 million
patients are prescribed this drug annually. Metformin was discovered before the era of target …

Epithelial/mesenchymal transition (EMT) has emerged as a key regulator of metastasis by
facilitating tumor cell invasion and dissemination to distant organs. Recent evidences …

Metformin is a widely used drug for treatment of type 2 diabetes with no defined cellular
mechanism of action. Its glucose-lowering effect results from decreased hepatic glucose …

Although metformin is widely used for the treatment of non-insulin-dependent diabetes, its
mode of action remains unclear. Here we provide evidence that its primary site of action is …

Insulin activated endogenous protein kinase B alpha (also known as RAC/Akt kinase)
activity 12‐fold in L6 myotubes, while after transfection into 293 cells PKBalpha was …

Metformin (dimethylbiguanide) is an orally administered drug used to lower blood glucose
concentrations in patients with non-insulin-dependent diabetes mellitus (NIDDM). 1 It …

Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all
current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become …

Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its
efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of …

Metformin is used for the treatment of type 2 diabetes because of its ability to lower blood
glucose. The effects of metformin are explained by the activation of AMP-activated protein …

To examine the mechanism by which moderate weight reduction improves basal and insulin-
stimulated rates of glucose metabolism in patients with type 2 diabetes, we used 1H …